Cummings, Jeffrey
Passmore, Peter
McGuinness, Bernadette
Mok, Vincent
Chen, Christopher
Engelborghs, Sebastiaan
Woodward, Michael
Manzano, Sagrario
Garcia-Ribas, Guillermo
Cappa, Stefano
Bertolucci, Paulo
Chu, Leung-Wing
Article History
Received: 16 April 2019
Accepted: 6 August 2019
First Online: 17 August 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Dr. Cummings has provided consultation to Acadia, Accera, Actinogen, Alkahest, Allergan, Alzheon, Avanir, Axsome, BiOasis, Biogen, Bracket, Denali, Diadem, EIP Pharma, Eisai, Forum, Genentech, Green Valley, Grifols, Hisun, Kyowa Kirin, Lilly, Lundbeck, Medavante, Merck, Otsuka, Pain Therapeutics, Proclera, QR, Resverlogix, Roche, Samus, Takeda, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in Prana, Neurokos, ADAMAS, MedAvante, QR pharma, Samus, Green Valley, and BiOasis. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.Professor Passmore has provided consultation to Pfizer, Eisai, J&J, Shire, Novartis, Lundbeck, Otsuka, MSD, and Nutricia.Dr. Chen has provided consultation to Accera, Allergan, Baxter, Danone, Eisai, Janssen, Lundbeck, Moleac, Novartis, Otsuka, Pfizer, and Wyeth pharmaceutical companies.Professor Cappa has provided consultation to Eli Lilly, Roche, Biogen, and Nutricia.All other authors declare that they have no competing interests.